Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. - Wikidata - wikimedia - TriplyDB

Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer.

Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer.

http://www.wikidata.org/entity/Q43899090

about

A soluble form of the giant cadherin Fat1 is released from pancreatic cancer cells by ADAM10 mediated ectodomain shedding Chromodomain-helicase-DNA binding protein 5, 7 and pronecrotic mixed lineage kinase domain-like protein serve as potential prognostic biomarkers in patients with resected pancreatic adenocarcinomas Neoadjuvant radiotherapeutic strategies in pancreatic cancer The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates Neoadjuvant therapy for pancreas cancer: past lessons and future therapies Comparing human pancreatic cell secretomes by in vitro aptamer selection identifies cyclophilin B as a candidate pancreatic cancer biomarker.Rapid characterization of candidate biomarkers for pancreatic cancer using cell microarrays (CMAs).Serum CA19-9 in patients with solid pancreatic mass.A varying-coefficient cox model for the effect of CA19-9 kinetics on overall survival in patients with advanced pancreatic cancer Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study Intensity of follow-up after pancreatic cancer resection The CA19-9 and Sialyl-TRA Antigens Define Separate Subpopulations of Pancreatic Cancer Cells Risk factors for pancreatic adenocarcinoma and prospects for screening.Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation Screening for pancreatic cancer: why, how, and who?Borderline resectable pancreatic cancer: definitions and management.Enhanced discrimination of malignant from benign pancreatic disease by measuring the CA 19-9 antigen on specific protein carriers Pancreatic adenocarcinoma Serum HSP70: a novel biomarker for early detection of pancreatic cancer.Gemcitabine-based chemoradiotherapy followed by surgery for borderline resectable and locally unresectable pancreatic ductal adenocarcinoma: significance of the CA19-9 reduction rate and intratumoral human equilibrative nucleoside transporter 1 expr Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704 The prognostic and predictive value of serum CA19.9 in pancreatic cancer Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials.Secretome-based identification of ULBP2 as a novel serum marker for pancreatic cancer detection.Clinical significance and revisiting the meaning of CA 19-9 blood level before and after the treatment of pancreatic ductal adenocarcinoma: analysis of 1,446 patients from the pancreatic cancer cohort in a single institution.Factors affecting long-term survival after surgical resection of pancreatic ductal adenocarcinoma.Urinary TIMP-1 and MMP-2 levels detect the presence of pancreatic malignancies.A Novel Multivariate Index for Pancreatic Cancer Detection Based On the Plasma Free Amino Acid Profile CA 19-9 as a serum marker in urothelial carcinoma.Pre-treatment carbohydrate antigen 19-9 does not predict the response to neoadjuvant therapy in patients with localized pancreatic cancer Comparative study of CA242 and CA19-9 for the diagnosis of pancreatic cancer Advances in biomarker research for pancreatic cancer.The prognostic value of serum CA 19-9 for patients with advanced lung adenocarcinoma.Correlation of CEA but not CA 19-9 as serum biomarkers of disease activity in a case of metastatic rectal adenocarcinoma.The Microbiome and Cancer: Is the 'Oncobiome' Mirage Real?Pancreatic Cancer: a Challenge to Cure Strategies for discovering novel pancreatic cancer biomarkers.CA 19-9 and pancreatic cancer.Serum CA 19-9 and CEA levels as a prognostic factor in pancreatic adenocarcinoma Diverse monoclonal antibodies against the CA 19-9 antigen show variation in binding specificity with consequences for clinical interpretation

P2860

Q21132301-18E121C3-EC32-41A9-A547-BADF79CB00CE Q26751724-52462D90-AA50-4766-92FD-EF7754B6401E Q26766686-DF193484-230E-4071-897E-F797233EE033 Q26865015-D7E48188-0944-423E-A1C7-C067882F983C Q27004292-3255502C-D18E-44F5-8661-6B5CD0879385 Q30513800-6932DCF4-5DAE-4445-8A66-20781B427A36 Q30534663-509BCB50-8C31-4808-8A0C-8696E7F1B43F Q33596555-8691FBAC-53C1-421E-9DAA-DC7CF9073E12 Q33728198-824233E6-B71B-4ABD-9DE8-817466B9F705 Q33780907-CE027592-A6A5-4F06-8795-B7F9D423D7E1 Q33791048-59E17FD2-1A6C-4243-8AF8-7E15F8130440 Q33826323-10E8F7F3-0EBB-4186-8F75-4790A55E7573 Q33916380-196CF143-7DBF-400C-9C75-E6E51FEAD694 Q33928253-3B879B34-386E-4E9E-A9C4-EA0028DCB320 Q33959412-C993CFA1-8619-4F03-B839-DD8EC63E8387 Q34067852-E73E666F-70D8-4AF4-93D2-4CEC671B736E Q34119094-40CAD643-C2EE-4334-A51A-70F9180CCF40 Q34140498-AC4A6620-C3D5-4F1D-9462-C1D43DEB9874 Q34322212-5CD43CE4-975F-4E57-A04E-F7E605A6A754 Q34408283-77AE35DD-1980-45EB-9839-0AB12335CA61 Q34600819-F3D691E5-1AE0-45BD-AE6D-8078C98C6992 Q34635104-BA78B40E-59AE-4C91-9D34-A1B1411F0EE4 Q34665177-FFF062C0-139A-4CEF-9A59-F35BE3612006 Q34995279-964151A6-8DBF-4F0D-889A-4984EEB7E8CE Q35046670-DBF72BD6-1417-42E5-A342-03F4CD2EBA63 Q35627199-F7C6B311-B6C9-4FC3-BAC1-A6FE08450747 Q35678051-6451F0C9-7A37-4340-B5F7-5A3AC53B4F0F Q35680475-8C8A4D22-0C64-4E58-91CD-B1ADA69135E5 Q35970605-7FC5A3BE-B9FE-4617-B5AC-6CCC36B933D5 Q36064780-864B1C2D-7F7F-4359-9D29-807DF0CB2BE4 Q36079626-7F3BC1F2-3664-432C-9F7B-F0D96A3AA564 Q36126609-311518B1-4913-4119-AC4E-F954696692F3 Q36191929-33C7A4B0-683C-43FE-B160-CE405E2C71D1 Q36213547-71A63231-1A87-4614-BB60-D93C100156AC Q36272668-E9A694A7-7EB2-48F9-A871-CF416D7825E7 Q36400081-589A6EDB-13EB-4E4E-98F6-96A3538C9D73 Q36579311-B2B26D58-446B-4C6B-9818-EF6CEA3924D6 Q36786361-55E4D922-8F30-487E-B1D3-DD2FE1B4C09A Q36793155-A2F5E6D4-8E12-46D9-8B49-613930A22121 Q37011364-529E75A4-4F4C-4EDE-B34E-B42A9CF6E1C5

P2860

Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer.

http://www.wikidata.org/entity/Q43899090

description

1987 nî lūn-bûn

@nan

1987年の論文

@ja

1987年学术文章

@wuu

1987年学术文章

@zh

1987年学术文章

@zh-cn

1987年学术文章

@zh-hans

1987年学术文章

@zh-my

1987年学术文章

@zh-sg

1987年學術文章

@yue

1987年學術文章

@zh-hant

name

Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer.

@en

Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer.

@nl

type

label

Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer.

@en

Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer.

@nl

prefLabel

Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer.

@en

Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer.

@nl

P1433

Q43899090-5463BC32-A1C0-4BE5-B6B6-6AAAAB5D2236

P1476

Q43899090-A02A190B-2C61-496F-BB6E-FDF6DDF64364

P2093

Q43899090-03D03DA1-D04B-447D-A76D-0E7CB43CA8B7

Q43899090-1A9B39F1-2231-4132-B967-1782921B6A92

Q43899090-4EC6EA27-F504-4E71-905B-680522FCB771

Q43899090-53126470-DB74-4498-957A-BD89478E2BFB

Q43899090-F2B97ED9-79C6-4045-9B8A-7A9A3749BD63

Q43899090-FABBA5EA-F5BB-4431-A804-967DD310DC03

P304

Q43899090-769A0D9F-26B4-4ABC-900C-25DD146D92D0

P31

Q43899090-5F176D52-49AF-4890-8A70-C4A09C59202B

P407

Q43899090-A7AA5A3E-8050-44DE-9DA7-0BF06EBBF103

P433

Q43899090-1B200037-B498-4D86-92D9-FCAC1571F584

P478

Q43899090-BCECC728-4B2E-44BE-9184-3773671C9C12

P577

Q43899090-A01780EF-2FA6-442D-87C2-42FF90F18450

P698

Q43899090-4EAE440C-D8F9-44E9-A8A2-EF119BA54C67

P1433

Cancer Research

P1476

Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer

@en

P2093

Burnett DA

http://www.w3.org/2001/XMLSchema#string

Pour PM

http://www.w3.org/2001/XMLSchema#string

Steplewski Z

http://www.w3.org/2001/XMLSchema#string

Takasaki H

http://www.w3.org/2001/XMLSchema#string

Tempero MA

http://www.w3.org/2001/XMLSchema#string

Uchida E

http://www.w3.org/2001/XMLSchema#string

P304

5501-5503

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P407

P433

20

http://www.w3.org/2001/XMLSchema#string

P478

47

http://www.w3.org/2001/XMLSchema#string

P577

1987-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

3308077

http://www.w3.org/2001/XMLSchema#string